{
    "clinical_study": {
        "@rank": "16453", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "Brimonidine Tartrate 0.025%", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and efficacy of brimonidine tartrate\n      0.025% ophthalmic solution used four times daily in a population of adult and geriatric\n      subjects"
        }, 
        "brief_title": "Study Evaluating the Safety and Efficacy of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Subjects", 
        "condition": "Ocular Redness", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Be at least 40 years of age\n\n          -  Must have normal ocular health\n\n          -  Must have history of redness relief drop use or desire to use\n\n        Exclusion Criteria:\n\n          -  Must not have any ocular/systemic health problems\n\n          -  Must agree to avoid disallowed medications"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "57", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01675609", 
            "org_study_id": "11-100-0015"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "1 drop in each eye daily for up to 35 days", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Brimonidine Tartrate 0.025%", 
                "description": "1 drop in each eye for up to 35 days", 
                "intervention_name": "Brimonidine tartrate 0.025%", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Brimonidine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "September 24, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Andover", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "01810"
                }, 
                "name": "Ora, Inc."
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Subjects", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "redness evaluated by investigator prior to study medication instillation and redness evaluated by the subject as captured in dosing diary", 
            "measure": "Ocular redness", 
            "safety_issue": "No", 
            "time_frame": "at specified timepoints for up to 180 minutes"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01675609"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "evaluated prior to study medication instillation and at 5 minutes post instillation", 
            "measure": "Ocular Redness", 
            "safety_issue": "No", 
            "time_frame": "up to 5 minutes post study medication instillation"
        }, 
        "source": "Eye Therapies, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eye Therapies, LLC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}